Patents
Sitemap › C07 - Organic chemistry › C07K - Peptides › C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320)
05/2003
05/29/2003US20030099649 Composition and method for treating inflammatory disorders
05/29/2003US20030099648 Comprises monoclonal sheep-derived antibodies and engineered antibody constructs, such as humanized single-chain Fv fragments and chimeric antibodies
05/29/2003US20030099647 Antigen binding domains; for treatment and prevention of autoimmune and inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis
05/29/2003US20030099646 For interfering with cyclin expression or phosphorylation via map-kinase; hybridomas; antitumor agents; antiproliferative agents
05/29/2003US20030099645 Treating human diseases by administering said immunoglobulin (IgM) having specificity to extracellular receptors on lymphocytes; prevents HIV infection, treating cancer; IgM developed at birth in absence of deliberate immunization
05/29/2003US20030099644 CD40 ligand and CD40 agonist compositions and methods of use
05/29/2003US20030099643 Methods for selectively stimulating proliferation of t cells
05/29/2003US20030099642 Inhibiting activation by CD40 ligand (CD40L) of cells bearing CD40 on the cell surface, other than B cells, by contacting with an agent that inhibits the interaction between CD40L and the cells; treating autoimmune diseases, for example
05/29/2003US20030099641 Does not bind to esterogen receptor (ER) alpha when not phosphorylated at Serine 118; use in drug screening, diagnosis, detection for breast cancer
05/29/2003US20030099639 Use in diagnosis; immunoassay
05/29/2003US20030099636 Administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained using homeopathic techniques; for example, treating drug dependence/drug withdrawal; side effect reduction
05/29/2003US20030099635 Use of oral gammaglobulin for the treatment of immune-mediated diseases
05/29/2003US20030099633 Methods and compositions for treatment of immune dysfunction disorders
05/29/2003US20030099627 Method for determining modulation of p110delta activity
05/29/2003US20030099625 Secreted and transmembrane polypeptides and nucleic acids encoding the same
05/29/2003US20030099611 Manipulation and detection of protein phosphatase 2c-pp2calpha - expression in tumor cells for cancer therapy, prevention and detection
05/29/2003US20030099610 Novel uses of avian interferon gamma (ifn-y)
05/29/2003US20030099609 Canine IL-4 nucleic acid molecules and uses thereof
05/29/2003US20030099608 Human cytokine receptor
05/29/2003US20030097974 Crystals and structure of Synagis Fab
05/28/2003EP1314779A1 Airway-specific trypsin-like enzymes and method of using the same
05/28/2003EP1314741A1 Bispecific anti-CD19 x anti-CD16 antibodies and uses thereof
05/28/2003EP1314740A1 METHOD OF CONSTRUCTING scFv ANTIBODY FUSED WITH FLUORESCENT PROTEIN
05/28/2003EP1314437A1 Stabilized antibody-containing preparations
05/28/2003EP1314037A2 Methods of designing and producing compounds having improved binding affinity for cd154 or other trimeric proteins
05/28/2003EP1314032A2 Compositions and methods for epitope mapping
05/28/2003EP1313875A2 Method of diagnosing, monitoring, staging, imaging and treating colon cancer
05/28/2003EP1313863A2 A recombinant monoclonal antibody to phosphotyrosine-containing proteins
05/28/2003EP1313857A2 Lipid metabolism molecules
05/28/2003EP1313855A2 Truncated bard1 protein, and its diagnostic and therapeutic uses
05/28/2003EP1313854A2 Transporters and ion channels
05/28/2003EP1313844A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
05/28/2003EP1313843A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
05/28/2003EP1313840A2 Isolated human drug-metabolizing proteins, nucleic acid molecules and uses thereof
05/28/2003EP1313771A2 Haemophilus influenzae lipopolysaccharide inner-core oligosaccharide epitopes as vaccines for the prevention of haemophilus influenzae infections
05/28/2003EP1313769A2 Antibodies to human il-1 beta
05/28/2003EP1313762A2 Suppressor gene
05/28/2003EP1313756A1 Antibodies specific for methylated lysines in histones
05/28/2003EP1313506A1 Immunologic method for the prevention of dental caries
05/28/2003EP1313504A2 Methods and compositions for inhibiting angiogenesis
05/28/2003EP1313503A1 Human tumor necrosis factor receptors tr21 and tr22
05/28/2003EP1313501A2 Functions for dp214
05/28/2003EP1165115B1 Modulation of vascular permeability by mean of tie2 receptor activators
05/28/2003EP1135500A4 Control of flowering
05/28/2003EP0686162B1 Improved method for the refolding of proteins
05/28/2003EP0576476B1 Immunoassay for detection of mutant p53 polypeptide in biological fluids
05/28/2003EP0449958B9 Meningococcal class 1 outer-membrane protein vaccine
05/28/2003CN1420930A Novel compounds
05/28/2003CN1420926A Anti-angiogenic proteins and fragments and methods of use thereof
05/28/2003CN1420893A Method and compositions for generating human monoclonal antibodies
05/28/2003CN1420789A Compound for targeting
05/28/2003CN1420786A Treatment of fungal infections with beta glucan synthase inhibitor antifungals combined with anti HSP90 antibodies
05/28/2003CN1420785A Method of treating cancer with anti-neurotrophin agents
05/28/2003CN1420129A Humanized anti-CD 20 monoclonal antibody
05/28/2003CN1420128A Humanized anti-HER 2 monoclonal antibody, its preparation method and pharmaceutical composition thereof
05/27/2003US6570061 Generating transgenic animal; obtain animal blastocyst, transform with expression vector coding immunoglobulin, propagate blastocyst and recover trangenic animal
05/27/2003US6570002 Inhibitor of programmed cell death
05/27/2003US6570001 Polynucleotides and their use for detecting resistance to streptogramin A or to streptogramin B and related compounds
05/27/2003US6569997 Antibody specific for H4-1BB
05/27/2003US6569996 Antibody that specifically binds to the cadherin-5 cell adhesion recognition sequence
05/27/2003US6569992 Protein for use in the treatment of immunological, liver, reproductive and infectious disorders
05/27/2003US6569666 Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
05/27/2003US6569664 Tumor necrosis factor (TNF); enzyme purification and characterization; regulation of TNF for use in treatment of inflammatory diseases and conditions
05/27/2003US6569658 Proteins and nucleic acids which have an effect on or are related to cell cycle regulation; use in assays screening for cell cycle modulators and as therapeutics
05/27/2003US6569655 For use in therapeutics, diagnostics, and as research tools
05/27/2003US6569642 TNF-Related Apoptosis-Inducing Ligand (TRAIL); isolated DNA probe which hybridizes to nucleic acid of given sequence; use in purifying cells, inhibiting biological activities or as immunogens to produce antibodies
05/27/2003US6569632 Monoclonal antibody probe for detection of adhesins associated with mature endospores of pasteuria SPP
05/27/2003US6569622 Nucleic acids encoding a protein conferring an inducible resistance to glycopeptide, particularly in gram-positive bacteria
05/27/2003US6569431 Polypeptide for use in the treatment of autoimmune disease and multiple sclerosis
05/27/2003US6569430 Antibodies to the antigen Campath-1
05/27/2003US6569429 Isolated polypeptide comprising the amino acid residues 1 to 344 of (SEQ ID NO: 2); systemic lupus erythematosus; pulmonary disease or disorder
05/27/2003US6569420 Human interferon-ε: a type I interferon
05/27/2003CA2273855C Novel feline fc epsilon receptor alpha chain nucleic acid molecules, proteins and uses thereof
05/27/2003CA2140866C Use of inhibitors of fatty acid synthesis for treating cancer
05/27/2003CA2096230C Characterization of platelet aggregation disorders
05/22/2003WO2003042413A1 Method and compositions for processing poultry feathers
05/22/2003WO2003042402A2 Agents that modulate immune cell activation and methods of use thereof
05/22/2003WO2003042401A2 Novel chromophores/fluorophores and methods for using the same
05/22/2003WO2003042399A2 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof
05/22/2003WO2003042390A1 Mammalian protein phosphatases
05/22/2003WO2003042386A1 Desmin gene having novel point mutation causative of dilated cardiomyopathy
05/22/2003WO2003042374A2 Isolation of neurones and stem cells for nerve fibres from a sample
05/22/2003WO2003042368A2 Methods of expressing lim mineralization protein in non-osseous cells
05/22/2003WO2003042367A2 Antibodies that immunospecifically bind to trail receptors
05/22/2003WO2003042366A2 A novel saitohin gene and uses of same
05/22/2003WO2003042362A2 PGC-1β, A NOVEL PGC-1 HOMOLOGUE AND USES THEREFOR
05/22/2003WO2003042359A2 Histamine receptor h3 polynucleotides
05/22/2003WO2003042357A2 Enzymes
05/22/2003WO2003042247A2 Modified anti-tnf alpha antibody
05/22/2003WO2003042245A2 Growth hormone variations in humans and their uses
05/22/2003WO2003042244A2 Immunogenic mimetics of multimer proteins with promiscuous t cell epitope inserts
05/22/2003WO2003042231A2 Bispecific anti-cd28 antibody molecule
05/22/2003WO2003042226A2 Single nucleotide polymorphisms in gh-1
05/22/2003WO2003041737A1 Treatment of inflammatory conditions
05/22/2003WO2003041736A2 Method for the treatment of cardiotoxicity induced by antitumor compounds
05/22/2003WO2003041731A2 Method to obtain protection against bystander allergen
05/22/2003WO2003041659A2 Method and identification of downstream mrna ligands to fmrp and their role in fragile x syndrome and associated disorders
05/22/2003WO2003041650A2 Modulation of lir function to treat rheumatoid arthritis
05/22/2003WO2003041637A2 Lyophilized monoclonal antibody compositions
05/22/2003WO2003041495A1 Chimeric nonhuman animal
1 ... 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 ... 1494